BioElectronics Corporation

BioElectronics has taken proven medical technologies and made them available to more people in new convenient, cost-effective, anti-inflammatory patches.  By applying advanced microelectronic technology, BioElectronics has dramatically reduced the size and the cost of some well-established medical treatments.


BioElectronics Corporation

Stock Symbol: (BIEL.Pk)

Makers of ActiPatch™ a drug-free,  anti-inflammatory patch that resolves swelling.

BioElectronics is the developer and marketer of  ActiPatch™ medical devices which deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing of soft tissue injuries. A reduction of pain and swelling allows patients to return to normal activities much sooner. This patented technology is based on clinically proven, widely accepted PEMF therapy.

The Company's ActiPatch is a drug-free, painless, pulsed energy patch. The ActiPatch has FDA clearance for the treatment of edema following blepharoplasty.

This could be a company that is very much in the right place at the right time!
 
 

For more information on Bioelectronics Corporation visit our websites at www.bioelectronicscorp.com

 

The Bioelectronics Solution Is:

  • Drug-free
  • Reduces swelling and inflammation
  • Lasts 10 to 30 days, depending on model
  • Comfortable
  • Provides Continuous Treatment
  • Easy to use
  • Safe
  • Affordable
  • Provides Localized, Non-Systemic Treatment
  • Lightweight

 

Company Accomplishments:

  • FDA market clearance for the treatment of edema
  • International Standards Organization (ISO) and CE (Conformité Européenne, French for European conformity) Certifications
  • Health Canada Market clearance for the relief of musculoskeletal pain
  • Strong intellectual property
  • Active sales and marketing support.

Clinical Trials

In 2006, the Company and the Lahey Clinic jointly announced a three-year program to study the effects of ActiPatch Therapy on a variety of soft tissue injuries and related medical conditions. The internationally renowned Lahey Clinic of Boston, whose faculty is affiliated with the Medical Schools of Harvard and Tufts, has committed to initiating a number of double-blind clinical studies on ActiPatch Therapy in the areas of plastic surgery, orthopedics and chronic wound care. Results from these clinical trials will be submitted to the United States Food and Drug Administration (the FDA) for expanded indications for the use of ActiPatch Therapy.

The company also commenced a series of double-blind clinical trials to be conducted in conjunction with leading schools of podiatry and selected clinics to document the effects of ActiPatch on treating plantar fasciitis [heel pain]. The studies started in March 2006. The Principal Investigator for the study is Dr. William Van der Reis, a Board Certified Orthopedic Surgeon and sports medicine specialist. The study protocol was approved by the Investigational Review Board, Coast IRB, of San Clemente, CA.

Physician Testimonials

Laurie Casas M.D.

FACS, Chair, Communications Commission, American Society for Aesthetic Plastic Surgery, Associate Professor, Northwestern University Feinberg School of Medicine

"I use ActiPatch on every facial procedure. It reduces my patients bruising and swelling by 50% following Blepharoplasty, Face Lifts and Rhinoplasty. As a result of ActiPatch two weeks of standard surgical recovery has been reduced to 5 to 7 days."   

David Lavine, M.D.

Fort Worth, Texas 

"I have a very large breast augmentation practice. After conducting a double-blind study, I have found that ActiPatch is extremely effective in curbing post-operative pain. In my professional opinion, ActiPatch is effective for short term control of the acute pain that occurs following breast surgery."  

Kimberley Goh, M.D., Myrtle Beach, SC

"ActiPatch has made a world of difference in post-op pain control in my patients. We apply ActiPatch to all abdominoplasty patients. The difference in pain control is amazing."   

William Van der Reis M.D.

Board Certified Orthopedic Surgeon, San Clemente, CA

"I have found that ActiPatch usually resolves pain associated with heel pain conditions such as plantar fasciitis in as little as 2-3 days. The potential for ActiPatch in the treatment of inflammatory conditions such as heel pain and acute sports injuries is enormous. The PEMF technology is safe and has been used for years, but until now it has not been available in a patch that a patient can wear at home."    

James Ricketti, DPM.

East Hanover, NJ

"I started using ActiPatch approximately one year ago and have been impressed with the results. It reduces pain and edema without medication. I started using ActiPatch on patients who had no insurance to get physical therapy, or who had failed therapy and other conservative care. The amount of pain relief and edema reduction is remarkable with the ActiPatch. The ActiPatch unit is safe and low cost, small, portable and a narcotic free, pain-free device."   

Steven Sheriden, DPM,

Sandusky, MI

"I have exposed 60 of my patients with heel pain to your ActiPatch device. This was instead of an oral NSAID. None were given steroid injestions on their initial visit, just the ActiPatch for endema control. Of the 60 patients, 4 returned the patch for a refund and one of the 4 patches was retuned because it had been mauled by their cat. I have had the amazing claims of no pain immediately after applying the device. The more common statement is that they can tell it is helping. The patients are excited about avoiding the cost of prescription medications. Some have to supplement with something OTC. All in all this has turned out to be a great option for my patients. It gives them a choice to avoid a shot or medication side effects. They appreciate your guarantee of a refund but are not taking advantage of it in my office. Thank you for the tips and customer support during my calls about your product." 

 

 

 

 
 
 

BioElectronics Corporation Stock Symbol: (BIEL.Pk)

BioElectronics Announces Addition of Sheryl Goldstein, DPM to Management Team 10/19/06

BioElectronics Announces Henry Schein, Inc Agreement
10/09/06

BioElectronics Announces New Address
10/04/06

Actipatch Featured in Biomechanic's Article in September Issue
09/18/06

BioElectronics Announces Two New Sales Agreements
09/11/06

BioElectronics National Sales Representation Program is Expanding Rapidly
08/28/06

BioElectronics Corporation Accelerates Introduction of Its Market
08/23/06

Disruptive Products and Updates Business Strategy
08/23/06

BioElectronics Corporation To Be Featured on Market News First Radio
08/09/06

BioElectronics Corporation Signs Major Distribution Agreement with OrthoPro LLC for Podiatry Market
07/25/06

BioElectronics Corporation Featured at VigilantTrader.com
07/11/06

 

 
 
This profile is not without bias, and is a paid release. Itsaboutfinance.tv (IAF) has been compensated for dissemination of company information on behalf of a third party. ( itsaboutfinance.tv has been compensated Two Thousand Dollars for coverage of BioElectronics Corporation (BIEL.PK), IAF holds forty thousand shares of stock. IAF may receive shares for extension of its services. Any shares will be disclosed at such time that IAF is aware of a clients desire to extend the original services, IAF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. IAF may immediately sell some or any shares in a profiled company held by IAF and may have previously sold shares in a profiled company held by IAF. IAF's services for a company may cause the company's stock price to increase, in which event IAF would make a profit when it sells its stock in a company. In addition, IAF's selling of a company's stock may have a negative effect on the market price of the stock.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Ad of 1933, as amended, and Section 21 E the Securities Exchange Ad of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or I O-KSO and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and IAF undertakes no obligation to update such statements.
 
 
This message brought to you by ItsAboutFinance.tv